Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.
Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost ...
Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating ...
The combination works by decreasing hunger and increasing the feeling of fullness. The REDEFINE 2 trial (ClinicalTrials.gov Identifier: NCT05394519) evaluated the efficacy and safety of CagriSema ...
Denmark-headquartered Novo Nordisk, a leading global healthcare company founded in 1923 to drive change to defeat serious chronic diseases built upon our heritage in diabetes, announced headline ...
Viyaara Realty, a premier Mumbai-based real estate developer, dedicated to creating exceptional living spaces is set to ...
Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...
The rise of influencer culture and targeted advertising have created an ecosystem where purchases are influenced more by ...
Novo Nordisk's experimental drug, CagriSema, demonstrated a 15.7% weight reduction in obese individuals with type 2 diabetes over 68 weeks. Key findings from the phase III REDEFINE 2 trial highlight ...
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback